Meeting
2019 ASCO Annual Meeting
Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.
Authors
Gal Cafri
National Cancer Institute Surgery Branch, Bethesda, MD
Gal Cafri , Jared J. Gartner , Kristen Hopson , Robert S. Meehan , Tal Z. Zaks , Paul Robbins , Steven A. Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT03480152
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2643)
DOI
10.1200/JCO.2019.37.15_suppl.2643
Abstract #
2643
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.
First Author: Mark Yarchoan
Poster
2022 ASCO Annual Meeting
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
First Author: Jean-Pierre Delord
Poster
2019 ASCO Annual Meeting
A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.
First Author: Roger B. Cohen
Poster
2023 ASCO Annual Meeting
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
First Author: Yang Zhang